AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04105062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LS301
Description: -LS301 is produced at the Optical Radiology Laboratory at Washington University School of Medicine
Study NCT04105062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancer Vision Goggles
Description: -Non-significant risk device
Study NCT05244434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Given standard of care ribociclib + AI or palbociclib + AI
Study NCT05244434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy of tumor tissue
Study NCT05244434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT05244434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Undergo analysis of previously collected tumor tissue
Study NCT04176081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Darolutamide will be administered orally as a tablet. Total daily dose is 1200 mg (2 tablets of 300 mg taken twice daily) for 6 months.
Study NCT04176081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix is administered by subcutaneous injection. The first dose of degarelix is 240 mg followed by monthly doses of 80 mg for a total treatment duration of 6 months.
Study NCT04176081 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
Study NCT04176081 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: The total radiotherapy dose for all subjects will be: 36.25 Gy in 5Fx. The study will not include elective nodal irradiation. Every fraction will have 3D image guidance (i.e. cone-beam CT).
Study NCT04172428 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional MRI (fMRI)
Description: fMRI will be done on 3 separate MRI scanners to compare.
Study NCT06404944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implantation
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech Implant EV Profile (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Placement healing abutment~4. Suturing the wound tightly
Study NCT06404944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implantation
Description: 1. Incision the mucosa at the alveolar ridge, mucosal-periosteal flap elevation~2. Placement of the Astra Tech OsseoSpeed® TX dental implant (Astra Tech Implant System®; Dentsply Sirona CIS, Sweden)~3. Guided bone regeneration with xenogeneic bone material Bio-oss® (Geistlich Pharma AG, Sweden) and collagen membrane Bio-Gide® (Geistlich Pharma AG, Sweden)~4. Suturing the wound tightly
Study NCT05948839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS treatment
Description: Participants will receive 3 sessions per day of 1800 pulses per session, lasting for 21 days. Individualized targets will be generated using the pBFS method.
Study NCT05948839 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS treatment
Description: The parameters in the sham arms are the same as the active stimulation groups. Stimulation was delivered by the same device as the active group fitted with a sham coil.
Study NCT05588245 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants will undergo the same SDoH screener (AHC-Health Related Social Needs Tool) as full intervention participants, which will serve as the basis for a one-time brief session with the clinical research coordinator that will involve review of a 'Resource Guide' that provides a listing of available community resources to meet common social needs. Participants in this arm will also complete other prenatal and postpartum data collection items over the course of the study (with the exception of qualitative interviews).
Study NCT05588245 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based prenatal/perinatal/postpartum patient navigator
Description: Uses Freeman's principles of navigation to enhance patient access to care (e.g., help patients manage appointments), promote patient self-efficacy (e.g., connect patients to community housing, food, transportation resources), and sustain engagement with the healthcare system (e.g., bridge perinatal and primary care).
Study NCT05106920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NMP
Description: Participants received the percutaneous electrical stimulation intervention. Specifically, this consisted of the application of a square wave biphasic electrical current, to cause a tolerable muscle contraction. The application was 10 stimulations of 10 seconds, with 10 seconds at rest between stimulations. A trained physiotherapist performed the PNM intervention.
Study NCT04688398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seal oil
Description: Consumption of seal oil once per day (at breakfast)
Study NCT04688398 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Consumption of vegetable oil once per day (at breakfast)
Study NCT05818319 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 12 hours ETI pause
Description: Patients with CF are randomly allocated to ETI pause lasting 12 hours.
Study NCT05818319 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 36 hours ETI pause
Description: Patients with CF are randomly allocated to ETI pause lasting either 36 hours.
Study NCT05818319 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 60 hours ETI pause
Description: Patients with CF are randomly allocated to ETI pause lasting either 60 hours.
Study NCT05168072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: m-Health app
Description: M-Health app is used to set weight loss targets and record body weights online. Participants learn the calories they consumed by using the m-Health APP and follow the APP for physical exercise
Study NCT05168072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional outpatient obesity management
Description: Diet and exercise guidance
Study NCT05168072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional outpatient obesity management
Description: Diet and exercise guidance
Study NCT05805007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZVS203e
Description: ZVS203e is a rAAV-mediated gene editing drug that silences RHO mutant protein expression by CRISPR/Cas9 editing system.
Study NCT06065228 — intervention group
Intervention type: OTHER
Intervention: AlgometRx Nociometer
Description: Physiologic characterization of disease activity
Study NCT05821465 — intervention group
Intervention type: DEVICE
Intervention: HeartWatch
Description: The HeartWatch monitoring device will be worn on the upper left arm for the same duration or up to 48 hours that the standard event recorder or holter monitor is worn. The subject will be provided with a HelpWear smartphone that is paired to the monitor and only used by the participant to tag any events that they may have during the Heartwatch monitoring session.
Study NCT06084247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curved KARL STORZ fetoscope
Description: The KARLZ STORZ curved scope is used to see the inside of a pregnant person's uterus during minimally invasive surgery, similar to conventional scopes. The curved scope is rounded and thought to help visualize the anterior placenta because of its position on the uterus.
Study NCT06084247 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Scopes
Description: The conventional scopes are regularly used during laser photocoagulation of placental anastomoses.
Study NCT05918861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcetrapib
Description: Cholesterol Ester Transfer Protein Inhibitor, 300 mg tablets
Study NCT05918861 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo tablets
Study NCT06482333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time for resumption of DOAC
Description: Time for resumption of DOAC
Study NCT06482333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Time for resumption of DOAC
Description: Time for resumption of DOAC
Study NCT05920785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of the level of interleukins in the blood, stool analysis for the intestinal microbiome, general clinical tests, glucose tolerance test, hormonal profile
Description: comprehensive laboratory and instrumental diagnostics in accordance with federal clinical guidelines on obesity (Peterkova V. A., 2021), including:~* general blood test, general urine test,~* biochemical blood analysis (total protein, urea, creatinine, total bilirubin, AST, ALT, total cholesterol, high and low density lipoproteins, triglycerides, uric acid, alkaline phosphatase, C-reactive protein),~* hormonal profile (T4 free, TSH, cortisol, C-peptide, fasting insulin, stimulated insulin),~* glycated hemoglobin,~* - glucose tolerance test,~* ultrasound examination of abdominal organs, kidneys (in the presence of arterial hypertension),~* blood pressure monitoring.~Special laboratory methods:~* Blood test to determine the level of HCRP, pro-inflammatory cytokines (leptin, IL-1b, IL-6, IL-8, tumor necrosis factor-α).~* analysis of feces for microbiota by MALDI-TOF mass spectrometry,~* bioimpedance measurement.
Study NCT06319872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral disulfiram
Description: 250 mg/day
Study NCT05289687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab / Hyaluronidase Injection
Description: Daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 1, 8, 15, and 22
Study NCT05289687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab / Hyaluronidase Injection
Description: Patients that are MRD Negative on Day 29 will receive daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57.
Study NCT05289687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab / Hyaluronidase Injection
Description: Patients that remain MRD positive on Day 29 will receive a combination of daratumumab-hyaluronidase 1800mg/ 30,000 units once weekly for 4 doses on Days 36, 43, 50, and 57 and chemotherapy selected from the combinations listed below:~* Cytarabine 3000 mg/m2, IV, Every 12 hours for 4 doses on Days 37 and 38~* Methotrexate 1000 mg/m2, IV, Over 24 hours on Day 36~OR~* Methotrexate, Starting dose 100 mg/m2, IV, Days 36, 46, 56~* Vincristine, 1.5 mg/m2 (2 mg cap), IV, Days 36, 46, 56~* Pegaspargase, 2000 IU/m2 (Capped at 3750 IU), IV Days 37, 57~* Methotrexate 15 mg, IT, Days 36, 56
Study NCT05289687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab / Hyaluronidase Injection
Description: All patients with MRD negative response after completion of previous course are eligible for daratumumab-hyaluronidase 1800mg/ 30,000 units every 2 weeks on Days 1,15, 29, 43, 57, 71, 85, and 99 for 8 doses.
Study NCT06235697 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 46Gy / 23 fractions of EBRT to pelvis and prostate + LDR or HDR boost to prostate~+ Adjuvant ADT: Unfavourable Intermediate Risk: 6 months or High / Very High Risk: 24 months
Study NCT06235697 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation SBRT only
Description: 25Gy / 5 fractions to pelvis + 40 Gy / 5 fractions to prostate (SBRT)
Study NCT06235697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADT
Description: Assigned at enrollment
Study NCT05830669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles of 5 min inflation of a blood-pressure cuff to 200 millimetres of mercury (mmHG) (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed.
Study NCT05830669 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham RIPC
Description: 3 cycles of 5 min inflation of a blood-pressure cuff to 20 mmHG to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed
Study NCT05958108 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SinergiAPS intervention
Description: Audit and feedback intervention, with the audit being based on patient-reported experiences and outcomes of patient safety.
Study NCT04212143 — intervention group
Intervention type: OTHER
Intervention: there is no intervention
Description: There is no intervention in this study. It is observational only.
Study NCT05962515 — intervention group
Intervention type: PROCEDURE
Intervention: ultrasound guided dry needling
Description: Dry needling was applied in the intervention room with sterile conditions the patient in the prone position.The low frequency (2-5 MHz) transducer is placed in the gluteal region in a slightly oblique position and sonographic scanning is started. First, the large mountain shadow of the iliac crest and gluteus maximus muscle is sonographically visualized in the midline. Then the transducer is shifted inferiorly until the sciatic notch is visualized. When the sciatic notch, sciatic nerve and the pear-shaped piriformis muscle above it are visualized, the patient's knee is flexed and the leg is rotated internally and externally, and the typical sliding motion of the piriformis muscle is observed. After the target point is determined, a 22 G spinal needle is applied from lateral to medial or from medial to lateral with in plane technique. The needle is inserted and withdrawn several times until the switch response in the piriformis muscle is observed and extinguished
Study NCT05648513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interwiev
Description: Parent Attitudes About Childhood Vaccines Survey (PACV) will be implemented to the patients consulting to Atatürk City Hospital. Subjects with vaccine hesitancy will be randomly distributed to groups, and in this way, experimental (n=26) and control (n=26) groups will be formed. Routine antenatal monitoring will be kept with the control group. With the experimental group, on the other hand, motivational interviewing method will be implemented for 4 sessions of about 45 minutes each. Interviews will be held at 4 separate weekends, 1 session for each. Interviews will be performed via online means or face to face.
Study NCT04701489 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Splenic ultrasound
Description: GE LOGIQ E10 device with C1-6 ultrasound probe
Study NCT05658952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microcatheter-derived FFR
Description: FFR pullback trace is obtained through the manual retrieval performed after the positioning of the microcatheter FFR in the distal portion of the vessel. The pullback speed should be steady and the overall duration would be between 20 and 40 seconds. Then, the Interventional Cardiologist has to decide the procedural plan according to the pullback trace aiming to obtain an optimal post-PCI result in terms of physiology. FFR with pullback can be repeated after stenting to check and correct the result if needed.
Study NCT05658952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angiography-derived FFR
Description: FFR pullback trace is automatically obtained after the 3-Dimensional reconstruction of the vessel through angiography derived FFR. Then, Interventional Cardiologist has to decide the procedural plan according to the pullback result aiming to obtain an optimal post-PCI result in terms of physiology. Angiography-derived FFR can be repeated after stenting to check and correct the result if needed.
Study NCT05658952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI
Description: Interventional Cardiologist will perform PCI plan according to his/her the evaluation of angiography.
Study NCT04698174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial Photorefractive keratectomy (tPRK) without laser polishing
Description: Transepithelial Photorefractive keratectomy (tPRK) with laser ablation of the corneal epithelium and stroma in a single-step procedure using the B+L Teneo 317 Model 2 Excimer Laser.
Study NCT04698174 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transepithelial Photorefractive keratectomy (tPRK) with laser polishing
Description: Transepithelial Photorefractive keratectomy (tPRK) using the B+L Teneo 317 Model 2 Excimer Laser with end-treatment laser polishing using a fixed thickness of the additional layer of 5 μm.
Study NCT04698174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Photorefractive keratectomy (PRK)
Description: Conventional Photorefractive keratectomy (PRK) with alcohol-assisted epithelium ablation. Then the aspheric ablation profile will be performed using the B+L Teneo 317 Model 2 Excimer Laser.
Study NCT05380102 — intervention group
Intervention type: DEVICE
Intervention: Telemetry monitoring
Description: All participants will be on standard telemetry monitoring for Heart Rate, Respiration Rate and movements using the gold standard (Electrocardiography and Capnography respectively).
Study NCT04544943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioLexa- Cohort 1
Description: Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult healthy subjects
Study NCT04544943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BioLexa- Cohort 2
Description: Twice daily application of topical BioLexa™ lotion, administered for 14 days in adult mild to moderate AD patients
Study NCT04544943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice daily (BID) application of placebo for 14 days
Study NCT04544943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily (BID) application of placebo for 14 days
Study NCT04544943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: Twice daily (BID) application of Gentamicin for 14 days
Study NCT04544943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gentamicin
Description: Twice daily (BID) application of Gentamicin for 14 days
Study NCT05380102 — intervention group
Intervention type: DEVICE
Intervention: Continuous monitoring through Earlysense
Description: EarlySense (USFDA approved ballistocardiography device) will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
Study NCT05380102 — intervention group
Intervention type: DEVICE
Intervention: Continuous monitoring through Dozee VS
Description: Dozee VS will be placed under the patients mattress to measure Heart Rate, Respiratory Rate and movements
Study NCT05489640 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention will be administered in this study.
Study NCT06419010 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with the use of L-PRF
Description: The study protocol is the same as the standard surgery one but with additional use of L-PRF membranes
Study NCT06419010 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard surgery
Description: The standard surgical treatment, taking place in the operating room under general anesthesia
Study NCT05885633 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endometrial sampling with pipelle
Description: Following oocyte retrieval while the patient was under anesthesia, endometrial tissue sampling was performed with the help of pipelle cannula. A portion of the endometrial tissue was put into RNA stabilization buffer (RNAlater) to be used in qPCR and stored at -20°C until the analysis. The remaining endometrial tissue was first fixed with 10% formalin, followed by paraffin blocking and prepared for immunohistochemical analysis.
Study NCT06442202 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced Nutritional Diet
Description: Food was provided during the intervention period 3 (three) times each day, i.e. breakfast, lunch and dinner. The food menu used a 30-day menu cycle. The characteristics of the Balanced Nutrition Diet that have been provided based on the distribution of the composition of the macronutrients that will be intervened in are as follows: 45-55% carbohydrates, 15-20% protein, and 20-25% fat (Ministry of Health 2014). The type of diet and portions that were given were the same for each menu unless there were certain food restrictions or allergies, and then the type of food was adjusted specifically to that individual. The calories that will be given range from 300-400 Cal for breakfast, 400-500 Cal for lunch, and 300-500 Cal for dinner.~The choice of carbohydrates should be varied and prioritise complex carbohydrates such as whole grains. The choice of protein type is prioritised from low-fat protein sources and half of it is vegetable protein.
Study NCT06442202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Education
Description: Nutritional education is provided via online Zoom meetings with the help of educational media in the form of PowerPoint presentations/videos before entering the intervention period. The educational material that will be provided is regarding Guidelines for Balanced Nutrition, Food Safety, and Healthy Lifestyles (stress management and sleep time). The subject's understanding of the material provided was evaluated using an online quiz platform.